Maharajah Ponnaiah

Fondation pour l’innovation en Cadiométabolisme et Nutrition
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Year:

2026

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with no effective curative therapies. Necroptosis, a regulated necrotic cell death pathway controlled by receptor-interacting protein kinase 1 (RIPK1), has emerged as a potential driver of inflammation and fibrosis in chronic liver disorders. We investigated the role of necroptosis in PSC and whether RIPK1 inhibition could modify disease course and progression. Spatial profiling of human PSC biopsies revealed that necroptosis primarily affects cholangiocytes, while apoptosis was more frequent in hepatocytes and nonbiliary cells. In vitro, necroptosis inhibition protected cholangiocytes, and RIPK1 deletion conferred resistance to TNF-mediated cytotoxicity. In a murine model of PSC, pharmacological RIPK1 inhibition reduced cholestatic injury, hepatic inflammation, and biliary fibrosis. Multiomic analyses comprehensively demonstrated reprogramming toward wild-type–like profiles following treatment. These findings identify necroptosis as a critical effector in PSC and highlight RIPK1 inhibition as a promising disease-modifying approach, opening the door to targeted necroptosis-based therapies for this otherwise untreatable disease.

Year:

2025

Fanconi Anemia (FA) is a genetic disorder marked by bone marrow failure and cancer risk. FA features continuous activation of the p53 pathway, leading to an exacerbated cellular response to stress and DNA damage and significantly altering cellular metabolism. Here, we pointed out for the first time the overexpression of ZMAT3, an RNA-binding protein, in murine FA-deficient hematopoietic cells. To elucidate the functions of ZMAT3 in the context of FA, we employed a two-pronged experimental approach. Initially, hematopoietic stem cells from FA knockout (FA-KO) mice with targeted downregulation of ZMAT3 and a human fibroblast cell line derived from an FA patient. Combining functional and Omics approaches, our study uncovers the critical involvement of ZMAT3 in enhancing the survival of FA-deficient cells by modulating sphingolipid metabolism and ferroptosis. ZMAT3 emerges as a pivotal factor in mitigating hematopoietic stem cell exhaustion during the initial stages of FA.

Year:

2024

Year:

2020

Collaborators (11)

Lawrence Serfaty

-

FRANCE
View details

Ida Chiara GUERRERA

Head Necker Proteomics

INSERM

FRANCE
View details

Franck Verdonk

Stanford University

UNITED STATES
View details

Axelle Cadoret

INSERM

FRANCE
View details

Nicolas Chignard

Associate Professor

Sorbonne Université

FRANCE
View details

MARIE LHOMME

Head of Lipidomics

-

FRANCE
View details

Marie-Laure Arcangeli

Université Paris-Saclay

FRANCE
View details

Jérémie Gautheron

INSERM

FRANCE
View details

Camille Lobry

Principal Investigator

-

FRANCE
View details

Ines Metatla

INSERM

FRANCE
View details

Tounsia AIT SLIMANE

Full Professor

Sorbonne Université Campus Pierre et Marie Curie

FRANCE
View details